<DOC>
	<DOCNO>NCT02846701</DOCNO>
	<brief_summary>The primary purpose protocol evaluate low plasma concentration ( ie daily take dose duloxetine ) patient relieve least 30 % neuropathic pain duloxetine treatment . The secondary purpose protocol determine plasmatic concentration peak ( ie 6 hour take duloxetine ) patient relieve least 30 % neuropathic pain duloxetine treatment . Others secondary purpose evaluate intensity neuropathic pain , assess degree pain relief evaluate sensation global improvement experience patient .</brief_summary>
	<brief_title>Determination Antidepressant Duloxetine Plasma Improve Knowledge Analgesic Action Antidepressants Chronic Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Inclusion criterion : age 40 75 year old relieve neuropathic pain 60 mg duloxetine treatment ( differential &gt; 30 % intensity neuropathic pain NRS , treatment initiation ) Exclusion criterion : concomitant treatment enoxacin , fluvoxamine , flecainide , propafenone , metoprolol , risperidone , verapamil , omeprazole , modafinil , mequitazine , propafenone , tamoxifen , Monoamine Oxidase Inhibitors .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Neuropathic pain</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Duloxetine</keyword>
	<keyword>Liquid Chromatography</keyword>
	<keyword>Mass Spectrometry</keyword>
</DOC>